CDMO News
Agenus Collaborates with Zydus on BOT/BAL Development and U.S. BioCDMO Launch
Agenus Inc. has signed definitive agreements with Zydus Lifesciences Ltd. to advance the clinical development and manufacturing of its immuno-oncology candidates, botensilimab and balstilimab (BOT/BAL). The collaboration includes a $75 million upfront payment to Agenus for the transfer of its biologics CMC facilities
4 June 2025